Table IV.
Experimental (IV) | Observational (OLS) | |||
---|---|---|---|---|
Outcome variable | No controls | Post-Lasso | No controls | Post-Lasso |
(1) | (2) | (3) | (4) | |
Panel A: Medical spending | ||||
Total spending (dollars/month) [admin] | 17.7 | 52.3 | 137.3** | 103.8* |
(79.0) | (59.4) | (68.6) | (61.9) | |
N = 3,239 | N = 3,152 | N = 2,208 | N = 2,140 | |
Drug spending [admin] | 13.8 | 12.8 | 26.3 | 7.3 |
(43.2) | (20.4) | (27.2) | (12.0) | |
N = 3,239 | N = 3,152 | N = 2,208 | N = 2,140 | |
Office spending [admin] | 9.9 | 3.1 | 12.2 | 8.7* |
(16.2) | (6.8) | (7.5) | (5.1) | |
N = 3,239 | N = 3,152 | N = 2,208 | N = 2,140 | |
Hospital spending [admin] | 36.1 | 45.2 | 118.0** | 83.4 |
(50.4) | (45.6) | (55.7) | (51.8) | |
N = 3,239 | N = 3,152 | N = 2,208 | N = 2,140 | |
Nonzero medical spending [admin] | 0.013 | 0.004 | 0.061*** | 0.036*** |
(0.018) | (0.016) | (0.014) | (0.012) | |
N = 3,239 | N = 3,152 | N = 2,208 | N = 2,140 | |
Panel B: Employment and productivity | ||||
Job promotion [admin] | 0.006 | 0.009 | 0.019 | 0.009 |
(0.022) | (0.021) | (0.014) | (0.015) | |
N = 4,146 | N = 4,130 | N = 2,840 | N = 2,828 | |
Job terminated [admin] | 0.022 | 0.023 | 0.080*** | 0.063*** |
(0.018) | (0.017) | (0.011) | (0.011) | |
N = 4,834 | N = 4,753 | N = 3,300 | N = 3,244 | |
Sick leave (days/year) [admin] | 0.322 | 0.224 | 0.275 | 0.068 |
(0.398) | (0.344) | (0.272) | (0.251) | |
N = 4,782 | N = 4,712 | N = 3,264 | N = 3,216 | |
Management priority on health/safety | 0.087*** | 0.077*** | 0.004 | 0.007 |
[survey] | (0.023) | (0.021) | (0.017) | (0.016) |
N = 3,566 | N = 3,514 | N = 2,410 | N = 2,376 | |
Productivity index [survey/admin] | 0.070 | 0.096 | 0.069 | 0.083 |
(0.092) | (0.085) | (0.073) | (0.067) | |
N = 3,309 | N = 3,300 | N = 2,245 | N = 2,240 | |
Panel C: Health status and behaviors | ||||
IL Marathon/10K/5K 2017 [admin] | 0.003 | 0.011 | 0.059*** | 0.024*** |
(0.014) | (0.011) | (0.008) | (0.006) | |
N = 4,834 | N = 4,817 | N = 3,300 | N = 3,287 | |
Campus gym visits (days/year) [admin] | 0.110 | 0.757 | 3.527*** | 2.160*** |
(1.309) | (0.656) | (0.813) | (0.425) | |
N = 4,834 | N = 4,817 | N = 3,300 | N = 3,287 | |
Ever screened [survey] | 0.060*** | 0.056*** | 0.073*** | 0.061*** |
(0.014) | (0.012) | (0.011) | (0.009) | |
N = 3,567 | N = 3,557 | N = 2,410 | N = 2,404 |
Notes. Each row and column reports estimates from a separate regression. The outcome in each regression is specified by the table row, and the (endogenous) focal independent variable is an indicator for completing the screening and health risk assessments (HRAs). For the IV specifications (columns (1)–(2)), the instrument is an indicator for inclusion in the treatment group, and observations include individuals in the control or treatment groups. For the OLS specifications (columns (3)–(4)), there is no instrument and observations are restricted to individuals in the treatment group. The control strategy is specified by the column. Post-Lasso controls include covariates selected by Lasso to predict either the dependent variable or the focal independent variable. The set of potential predictors include baseline values of all available variables in the same family of outcomes, strata variables, and the baseline (2016) survey variables reported in Table I, as well as all two-way interactions between these predictors. Robust standard errors are reported in parentheses. */**/*** indicates significance at the 10%/5%/1% level using conventional inference.